eligibility_summary
Eligibility: Histologically confirmed DLBCL, relapsed/refractory after ≥2 prior systemic therapies, with measurable disease. Exclusions: pregnancy/breastfeeding, active or reactivated infection, active autoimmune disease or immune deficiency, severe organ failure (LVEF<40%, DLCO<40%, eGFR<30 mL/min, bilirubin ≥3×ULN), dependent on sponsor/investigator/site.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06481826 evaluates glofitamab monotherapy in Chinese patients with relapsed/refractory diffuse large B‑cell lymphoma after ≥2 prior lines. Drug/intervention: Glofitamab (bispecific monoclonal antibody, T‑cell–engaging IgG, 2:1 format) targets CD20 on B cells and CD3 on T cells. Mechanism of action: Simultaneously binds CD20 and CD3 to form an immune synapse, activating TCR/CD3 signaling in patient T cells and redirecting them to kill malignant B cells via perforin/granzyme‑mediated cytotoxicity, leading to B‑cell depletion, immunotherapy. Cells/pathways targeted: CD20+ malignant B cells in DLBCL, CD3 on T cells, T‑cell activation and cytolytic pathways, with associated cytokine signaling. Aim: assess safety and efficacy of single‑agent glofitamab in this population.